BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pletal cilostazol: Phase IV data

The double-blind, Japanese Phase IV CSPS 2 trial in 2,757 patients showed that Pletal was non-inferior to aspirin on the primary endpoint of the incidence of stroke (cerebral infarction, cerebral hemorrhage or subarachnoid hemorrhage). Specifically,...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >